New drug cenobamate tested in real life for stubborn seizures
NCT ID NCT06716801
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is tracking 300 adults with focal epilepsy whose seizures are not well controlled despite trying 2-3 other medications. Researchers are observing how well cenobamate works when added to their current treatment in real-world clinics across France, Germany, and Spain. The main goal is to see how many patients have at least a 50% reduction in seizures after 6 and 12 months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cenobamate (a drug to reduce seizures)
- What this could lead to
- If successful, this study could show that cenobamate helps more people with hard-to-control focal seizures achieve better seizure control in everyday clinical practice.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also relatively small (300 participants) and early in real-world use, so findings may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY WITH AND WITHOUT SECONDARY GENERALIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital TARNIER COCHIN
RECRUITINGParis, France, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.